Twenty-five year results of the national cancer institute randomized breast conservation trial

Nicole L. Simone, Tu Dan, Joanna Shih, Sharon L. Smith, Linda Sciuto, Elena Lita, Marc E Lippman, Eli Glatstein, Sandra M. Swain, David N. Danforth, Kevin Camphausen

Research output: Contribution to journalArticle

46 Citations (Scopus)

Abstract

Breast conservation therapy (BCT) consisting of lumpectomy and postoperative radiation has become an accepted alternative to mastectomy (MRM) for the treatment of early stage breast cancer. We currently report the 25 year outcomes of a single institution, prospective, randomized clinical trial at the National Cancer Institute. 237 women with pathologically confirmed invasive breast tumors 5 cm or less were accrued between 1979 and 1987 and randomized to receive either BCT or MRM. Overall survival was the primary endpoint. Patients with node positive disease were included and treated with doxorubicin and cyclophosphamide. Both arms received axillary dissection. BCT patients had radiation to the whole breast followed by a boost. At a median follow-up of 25.7 years, overall survival was 43.8% for the MRM group and 37.9% for BCT (P = 0.38). Although the cumulative incidence of a disease-free survival event was higher in BCT patients (29.0% MRM vs. 56.4% BCT, P = 0.0017), the additional treatment failures were primarily isolated ipsilateral breast tumor recurrences (IBTR's) requiring salvage mastectomy. 22.3% of BCT patients experienced an IBTR. Distant disease and second cancers were similar in both arms. After 25 years, long term survival between BCT and MRM continues to be similar in patients treated for early stage breast cancer. Patients receiving BCT may be at risk for additional treatment-related morbidity, which may occur as a late event. Further studies are required to delineate patients at higher risk for these events, and prolonged follow up should be encouraged after treatment for all women.

Original languageEnglish
Pages (from-to)197-203
Number of pages7
JournalBreast Cancer Research and Treatment
Volume132
Issue number1
DOIs
StatePublished - Feb 1 2012

Fingerprint

Segmental Mastectomy
National Cancer Institute (U.S.)
Breast
Breast Neoplasms
Mastectomy
Survival
Arm
Radiation
Recurrence
Second Primary Neoplasms
Treatment Failure
Doxorubicin
Cyclophosphamide
Disease-Free Survival
Dissection
Therapeutics
Randomized Controlled Trials
Morbidity

Keywords

  • Breast conserving therapy
  • Mastectomy
  • Radiation
  • Randomized

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this

Simone, N. L., Dan, T., Shih, J., Smith, S. L., Sciuto, L., Lita, E., ... Camphausen, K. (2012). Twenty-five year results of the national cancer institute randomized breast conservation trial. Breast Cancer Research and Treatment, 132(1), 197-203. https://doi.org/10.1007/s10549-011-1867-6

Twenty-five year results of the national cancer institute randomized breast conservation trial. / Simone, Nicole L.; Dan, Tu; Shih, Joanna; Smith, Sharon L.; Sciuto, Linda; Lita, Elena; Lippman, Marc E; Glatstein, Eli; Swain, Sandra M.; Danforth, David N.; Camphausen, Kevin.

In: Breast Cancer Research and Treatment, Vol. 132, No. 1, 01.02.2012, p. 197-203.

Research output: Contribution to journalArticle

Simone, NL, Dan, T, Shih, J, Smith, SL, Sciuto, L, Lita, E, Lippman, ME, Glatstein, E, Swain, SM, Danforth, DN & Camphausen, K 2012, 'Twenty-five year results of the national cancer institute randomized breast conservation trial', Breast Cancer Research and Treatment, vol. 132, no. 1, pp. 197-203. https://doi.org/10.1007/s10549-011-1867-6
Simone, Nicole L. ; Dan, Tu ; Shih, Joanna ; Smith, Sharon L. ; Sciuto, Linda ; Lita, Elena ; Lippman, Marc E ; Glatstein, Eli ; Swain, Sandra M. ; Danforth, David N. ; Camphausen, Kevin. / Twenty-five year results of the national cancer institute randomized breast conservation trial. In: Breast Cancer Research and Treatment. 2012 ; Vol. 132, No. 1. pp. 197-203.
@article{3dc96ba997824d888a24e9bcb90d34b0,
title = "Twenty-five year results of the national cancer institute randomized breast conservation trial",
abstract = "Breast conservation therapy (BCT) consisting of lumpectomy and postoperative radiation has become an accepted alternative to mastectomy (MRM) for the treatment of early stage breast cancer. We currently report the 25 year outcomes of a single institution, prospective, randomized clinical trial at the National Cancer Institute. 237 women with pathologically confirmed invasive breast tumors 5 cm or less were accrued between 1979 and 1987 and randomized to receive either BCT or MRM. Overall survival was the primary endpoint. Patients with node positive disease were included and treated with doxorubicin and cyclophosphamide. Both arms received axillary dissection. BCT patients had radiation to the whole breast followed by a boost. At a median follow-up of 25.7 years, overall survival was 43.8{\%} for the MRM group and 37.9{\%} for BCT (P = 0.38). Although the cumulative incidence of a disease-free survival event was higher in BCT patients (29.0{\%} MRM vs. 56.4{\%} BCT, P = 0.0017), the additional treatment failures were primarily isolated ipsilateral breast tumor recurrences (IBTR's) requiring salvage mastectomy. 22.3{\%} of BCT patients experienced an IBTR. Distant disease and second cancers were similar in both arms. After 25 years, long term survival between BCT and MRM continues to be similar in patients treated for early stage breast cancer. Patients receiving BCT may be at risk for additional treatment-related morbidity, which may occur as a late event. Further studies are required to delineate patients at higher risk for these events, and prolonged follow up should be encouraged after treatment for all women.",
keywords = "Breast conserving therapy, Mastectomy, Radiation, Randomized",
author = "Simone, {Nicole L.} and Tu Dan and Joanna Shih and Smith, {Sharon L.} and Linda Sciuto and Elena Lita and Lippman, {Marc E} and Eli Glatstein and Swain, {Sandra M.} and Danforth, {David N.} and Kevin Camphausen",
year = "2012",
month = "2",
day = "1",
doi = "10.1007/s10549-011-1867-6",
language = "English",
volume = "132",
pages = "197--203",
journal = "Breast Cancer Research and Treatment",
issn = "0167-6806",
publisher = "Springer New York",
number = "1",

}

TY - JOUR

T1 - Twenty-five year results of the national cancer institute randomized breast conservation trial

AU - Simone, Nicole L.

AU - Dan, Tu

AU - Shih, Joanna

AU - Smith, Sharon L.

AU - Sciuto, Linda

AU - Lita, Elena

AU - Lippman, Marc E

AU - Glatstein, Eli

AU - Swain, Sandra M.

AU - Danforth, David N.

AU - Camphausen, Kevin

PY - 2012/2/1

Y1 - 2012/2/1

N2 - Breast conservation therapy (BCT) consisting of lumpectomy and postoperative radiation has become an accepted alternative to mastectomy (MRM) for the treatment of early stage breast cancer. We currently report the 25 year outcomes of a single institution, prospective, randomized clinical trial at the National Cancer Institute. 237 women with pathologically confirmed invasive breast tumors 5 cm or less were accrued between 1979 and 1987 and randomized to receive either BCT or MRM. Overall survival was the primary endpoint. Patients with node positive disease were included and treated with doxorubicin and cyclophosphamide. Both arms received axillary dissection. BCT patients had radiation to the whole breast followed by a boost. At a median follow-up of 25.7 years, overall survival was 43.8% for the MRM group and 37.9% for BCT (P = 0.38). Although the cumulative incidence of a disease-free survival event was higher in BCT patients (29.0% MRM vs. 56.4% BCT, P = 0.0017), the additional treatment failures were primarily isolated ipsilateral breast tumor recurrences (IBTR's) requiring salvage mastectomy. 22.3% of BCT patients experienced an IBTR. Distant disease and second cancers were similar in both arms. After 25 years, long term survival between BCT and MRM continues to be similar in patients treated for early stage breast cancer. Patients receiving BCT may be at risk for additional treatment-related morbidity, which may occur as a late event. Further studies are required to delineate patients at higher risk for these events, and prolonged follow up should be encouraged after treatment for all women.

AB - Breast conservation therapy (BCT) consisting of lumpectomy and postoperative radiation has become an accepted alternative to mastectomy (MRM) for the treatment of early stage breast cancer. We currently report the 25 year outcomes of a single institution, prospective, randomized clinical trial at the National Cancer Institute. 237 women with pathologically confirmed invasive breast tumors 5 cm or less were accrued between 1979 and 1987 and randomized to receive either BCT or MRM. Overall survival was the primary endpoint. Patients with node positive disease were included and treated with doxorubicin and cyclophosphamide. Both arms received axillary dissection. BCT patients had radiation to the whole breast followed by a boost. At a median follow-up of 25.7 years, overall survival was 43.8% for the MRM group and 37.9% for BCT (P = 0.38). Although the cumulative incidence of a disease-free survival event was higher in BCT patients (29.0% MRM vs. 56.4% BCT, P = 0.0017), the additional treatment failures were primarily isolated ipsilateral breast tumor recurrences (IBTR's) requiring salvage mastectomy. 22.3% of BCT patients experienced an IBTR. Distant disease and second cancers were similar in both arms. After 25 years, long term survival between BCT and MRM continues to be similar in patients treated for early stage breast cancer. Patients receiving BCT may be at risk for additional treatment-related morbidity, which may occur as a late event. Further studies are required to delineate patients at higher risk for these events, and prolonged follow up should be encouraged after treatment for all women.

KW - Breast conserving therapy

KW - Mastectomy

KW - Radiation

KW - Randomized

UR - http://www.scopus.com/inward/record.url?scp=84857920242&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84857920242&partnerID=8YFLogxK

U2 - 10.1007/s10549-011-1867-6

DO - 10.1007/s10549-011-1867-6

M3 - Article

VL - 132

SP - 197

EP - 203

JO - Breast Cancer Research and Treatment

JF - Breast Cancer Research and Treatment

SN - 0167-6806

IS - 1

ER -